NCT01498484

Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies

A Phase II Study of the Therapeutic Effects Of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 87 (actual)
• Sponsor: Atara Biotherapeutics · Industry
• Sex: All
• Age: —
• Healthy volunteers: Accepted

Summary

This is a Phase II trial to evaluate the efficacy and safety of human leukocyte antigen (HLA) partially-matched third-party allogeneic Epstein-Barr virus cytotoxic T lymphocytes (EBV-CTLs) for the treatment of EBV-induced lymphomas and EBV-associated malignancies.

Conditions

• EBV-induced Lymphomas
• EBV-associated Malignancies
• Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma

Interventions

Type	Name	Description
BIOLOGICAL	EBV-specific T cells (EBV-CTLs)	EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.

Timeline

• Start date: 2011-12-01
• Primary completion: 2019-07-01
• Completion: 2019-07-01
• First posted: 2011-12-23
• Last updated: 2022-10-21
• Results posted: 2022-10-21

Locations

1 site across 1 country: United States